The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 1 study; full analysis set, data as observed.
OTEZLA improves skin clearance in biologic-naïve patients, with response maintained up to 2 years1,2
Baseline
Week 16 PASI-45 result
Individual results may vary.
Week 32 PASI-68 result
Individual results may vary.
*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.
BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.
aLIBERATE study. Data as observed among patients with a value at the time point indicated, with no imputation for missing values.
OTEZLA improves skin clearance in biologic-naïve
patients, with response maintained up to 2 years2,3
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.